ENGNE
enGene issues EX-99.1 corporate presentation
The company distributed an investor presentation outlining views on its non-viral genetic medicine pipeline, specifically detailing findings on its market research, commercialization strategy, and the anticipated regulatory pathway for its product candidate detalimogene.